These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11057343)

  • 1. A laboratory model to determine the uptake and release of olopatadine by soft contact lenses.
    Dassanayake NL; Carey TC; Owen GR
    Acta Ophthalmol Scand Suppl; 2000; (230):16-7. PubMed ID: 11057343
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug.
    Ohmori K; Hayashi K; Kaise T; Ohshima E; Kobayashi S; Yamazaki T; Mukouyama A
    Jpn J Pharmacol; 2002 Apr; 88(4):379-97. PubMed ID: 12046981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability.
    Beauregard C; Stephens D; Roberts L; Gamache D; Yanni J
    J Ocul Pharmacol Ther; 2007 Aug; 23(4):315-20. PubMed ID: 17803429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein limits the brain penetration of olopatadine hydrochloride, H1-receptor antagonist.
    Mimura N; Nagata Y; Kuwabara T; Kubo N; Fuse E
    Drug Metab Pharmacokinet; 2008; 23(2):106-14. PubMed ID: 18445990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo performance of epinastine hydrochloride-releasing contact lenses.
    Minami T; Ishida W; Kishimoto T; Nakajima I; Hino S; Arai R; Matsunaga T; Fukushima A; Yamagami S
    PLoS One; 2019; 14(1):e0210362. PubMed ID: 30699147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.
    Vogelson CT; Abelson MB; Pasquine T; Stephens DM; Gamache DA; Gross RD; Robertson SM; Yanni JM
    Allergy Asthma Proc; 2004; 25(1):69-75. PubMed ID: 15055565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.
    Brodsky M; Berger WE; Butrus S; Epstein AB; Irkec M
    Eye Contact Lens; 2003 Apr; 29(2):113-6. PubMed ID: 12695716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug].
    Ohmori K; Ikemura T; Kobayashi H; Mukouyama A
    Nihon Yakurigaku Zasshi; 2001 Jul; 118(1):51-8. PubMed ID: 11496828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of olopatadine for the treatment of ocular allergy.
    Abelson MB
    Expert Opin Pharmacother; 2004 Sep; 5(9):1979-94. PubMed ID: 15330735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
    Abelson MB; Spitalny L
    Am J Ophthalmol; 1998 Jun; 125(6):797-804. PubMed ID: 9645717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%.
    Artal MN; Luna JD; Discepola M
    Acta Ophthalmol Scand Suppl; 2000; (230):64-5. PubMed ID: 11057355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergic conjunctivitis and contact lenses: experience with olopatadine hydrochloride 0.1% therapy.
    Brodsky M
    Acta Ophthalmol Scand Suppl; 2000; (230):56-9. PubMed ID: 11057353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
    Leonardi A; Abelson MB
    Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model.
    Deschenes J; Discepola M; Abelson M
    Acta Ophthalmol Scand Suppl; 1999; (228):47-52. PubMed ID: 10337433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Opatanol].
    Johansen S
    Ugeskr Laeger; 2003 Jul; 165(30):2957. PubMed ID: 12926197
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis.
    Yaylali V; Demirlenk I; Tatlipinar S; Ozbay D; Esme A; Yildirim C; Ozden S
    Acta Ophthalmol Scand; 2003 Aug; 81(4):378-82. PubMed ID: 12859265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
    Yanni JM; Stephens DJ; Miller ST; Weimer LK; Graff G; Parnell D; Lang LS; Spellman JM; Brady MT; Gamache DA
    J Ocul Pharmacol Ther; 1996; 12(4):389-400. PubMed ID: 8951675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model.
    Abelson MB; Welch DL
    Acta Ophthalmol Scand Suppl; 2000; (230):60-3. PubMed ID: 11057354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and artificial tears in seasonal allergic conjunctivitis.
    Kamis U; Ozturk BT; Ozkagnici A; Gunduz K
    Acta Ophthalmol Scand; 2006 Feb; 84(1):148-9. PubMed ID: 16445458
    [No Abstract]   [Full Text] [Related]  

  • 20. Histamine H1-receptor antagonistic drug olopatadine suppresses TSLP in atopic dermatitis model mice.
    Higashi M; Ohsawa I; Oda F; Yamada Y; Kawana S; Iida K; Mitsuishi T
    Allergol Int; 2013 Mar; 62(1):137-8. PubMed ID: 23172358
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.